Eli Lilly and Company logo

Eli Lilly and Company (LLY)

Market Open
16 Oct, 07:28 PM
NYSE NYSE
$
1,256. 47
+4.86
+0.3883%
$
1.11T Market Cap
104.2 P/E Ratio
0.05% Div Yield
1.62M Volume
6.64 Eps
$ 1,251.61
Previous Close
Add Transaction
Day Range
1,251.25 1,274.56
Year Range
783.85 1,292.65
Want to track LLY and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

LLY trading today higher at $1,256.47, an increase of 0.3883% from yesterday's close, completing a monthly increase of 8.7853% or $101.47. Over the past 12 months, LLY stock gained 16.7289%.
LLY pays dividends to its shareholders, with the most recent payment made on Sep 10, 2026. The next estimated payment will be in In 1 month on Dec 10, 2026 for a total of $1.73.
The last earnings report, released on May 07, 2026, missed the consensus estimates by -7.35%. On average, the company has fell short of earnings expectations by -4.3733%, based on the last three reports.
Eli Lilly and Company has completed 4 stock splits, with the recent split occurring on Oct 16, 1997.
The company's stock is traded on 18 different exchanges and in various currencies, with the primary listing on NYSE (USD).

LLY Chart

People also search for

AbbVie Inc.
$ 285.39
+0.7022%
UNH
UnitedHealth Group Incorporated
$ 402.23
-1.0918%
NVS
Novartis AG Sponsored ADR
$ 150.5
+0.0798%
Forget Zepbound: 3 Newer Drugs That Could Power Eli Lilly's Next Leg Higher

Forget Zepbound: 3 Newer Drugs That Could Power Eli Lilly's Next Leg Higher

Eli Lilly could continue to dominate the weight-loss market thanks to medicines like Foundayo and retatrutide. The company's latest approval strengthens its diabetes portfolio.

Fool | 51 minutes ago
Here's Why Eli Lilly (LLY) Fell More Than Broader Market

Here's Why Eli Lilly (LLY) Fell More Than Broader Market

Eli Lilly (LLY) reached $1 at the closing of the latest trading day, reflecting a -1.04% change compared to its last close.

Zacks | 2 days ago
Prediction: Eli Lilly Could Have More Room to Grow Than Its Valuation Suggests

Prediction: Eli Lilly Could Have More Room to Grow Than Its Valuation Suggests

Eli Lilly trades at a premium multiple, yet its revenue growth dwarfs every major pharma peer by a wide margin. Whether that gap justifies buying shares near all-time highs depends on one critical assumption about Lilly's pipeline.

247wallst | 3 days ago

Eli Lilly and Company Investors

Name Quantity Cost Value Profit ($) Gain (%)
KH
Kevin Heal ARGUS INVESTORS' COUNSEL Inc.
4,011 $1.53M $5.05M $3.53M 231.24%
TJD
Thomas John Drogan PR Inc.IPAL SECURITIES Inc.
23,901 $18.46M $29.91M $11.46M 62.06%
DI
David Izzi Brown, LISLE/CUMMINGS Inc.
3,308 $1.67M $4.17M $2.49M 148.76%
Michelle S. Hickox
Michelle S. Hickox FIRST FINANCIAL BANKSHARES Inc.
850 $544,055.1 $1.08M $531,050.4 97.61%
Timothy M. Bidwell
Timothy M. Bidwell Hazlett, BURT & WATSON Inc.
2,569 $1.79M $3.27M $1.48M 82.72%

Eli Lilly and Company Analysts

Name Quantity Cost Value Profit ($) Gain (%)
SS
Steve Scala TD Cowen
79.94 $93,545.98 $100,314.06 $6,768.08 7.24%
TH
Trung Huynh RBC Capital
87.67 $104,600.88 $110,422.74 $5,821.86 5.57%

Eli Lilly and Company (LLY) FAQ

What is the stock price today?

The current price is $1,256.47.

On which exchange is it traded?

Eli Lilly and Company is listed on NYSE.

What is its stock symbol?

The ticker symbol is LLY.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0.05%.

What is its market cap?

As of today, the market cap is 1.11T.

Has Eli Lilly and Company ever had a stock split?

Eli Lilly and Company had 4 splits and the recent split was on Oct 16, 1997.

Eli Lilly and Company Profile

Pharmaceuticals Industry
Healthcare Sector
David A. Ricks CEO
NYSE Exchange
532457108 CUSIP
US Country
50,000 Employees
14 Aug 2026 Last Dividend
16 Oct 1997 Last Split
13 Jan 1978 IPO Date

Overview

Eli Lilly and Company is a global leader in the discovery, development, and marketing of human pharmaceuticals. With a history dating back to 1876, the company has established itself as a key player in the pharmaceutical industry, offering a wide range of products aimed at treating a variety of conditions. Headquartered in Indianapolis, Indiana, Eli Lilly and Company has forged multiple collaborations with other pharmaceutical giants such as Incyte Corporation, Boehringer Ingelheim Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd, Genentech, Inc., Biologics, Inc., AbCellera Biologics Inc., and Chugai Pharmaceutical Co., Ltd., enhancing its product offerings and research capabilities across different therapeutic areas.

Products and Services

  • Diabetes Care

    Includes a comprehensive portfolio of insulin and other diabetes treatments: Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500. Additionally, the company offers Jardiance, Mounjaro, and Trulicity for managing type 2 diabetes.

  • Oncology

    Provides a range of products for cancer treatment, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio, focusing on different types of cancer and treatment approaches.

  • Immunology

    Olumiant is offered for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19. Taltz is available for treating plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis.

  • Digestive Diseases

    Omvoh is targeted at ulcerative colitis, reflecting the company's commitment to addressing gastrointestinal disorders.

  • Neurological Disorders

    Includes Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is provided for migraine prevention and treatment of episodic cluster headache.

  • Other Therapeutic Areas

    The company also offers Cialis for erectile dysfunction and benign prostatic hyperplasia; Forteo for osteoporosis treatment; Zepbound for obesity management; and Ebglyss for severe atopic dermatitis, showcasing Eli Lilly's diverse portfolio catering to various health conditions.

Contact Information

Address: Lilly Corporate Center
Phone: 317 276 2000